Co-funded by the European Union

EIT Health Call for Proposals

EIT Regional Innovation Booster Poland 2026

Under EIT Cross-KIC RII Cluster Call

EIT Health

Munich

www.eithealth.eu

Table of Contents

Change Log **3**

Abbreviations **4**

Definitions **5**

Call Fact Sheet **6**

1 Introduction **7**

2 Description of the Call Objectives and Scope **8**

2.1 Programme Description 8

3 Call Criteria **11**

3.1 Application Admissibility 11

3.2 Application Eligibility Conditions 11

3.3 EU Restrictions on Participation 13

3.4 Applicant Exclusion Criteria 14

3.5 Integrity, conduct and conflict of interest on the part of applicants and participants 16

3.6 Contracting Requirements for Successful Applicants 16

4 Application Process **17**

4.1 Call and Programme Timeline 17

4.2 Use of Artificial Intelligence 18

5 Evaluation Procedure **19**

5.1 Evaluation Criteria & Scoring 19

5.2 Evaluation Process 21

5.3 Evaluation methodology 21

5.4 Communication of evaluation results to applicants 22

5.5 Standstill Period 22

5.6 Publication of Call Results 23

6 Project Monitoring **24**

6.1 Monitoring During and After Participation 24

7 Grounds for Appeal and Appeal Procedure **25**

7.1 Appeals Procedure 25

8 Where to Get Help **26**

8.1 Call Information Webinars 26

8.2 Frequently Asked Questions (FAQ) 26

8.3 Contact for Support 26

9 Other Terms and Conditions **27**

9.1 Acceptance of the call conditions 27
9.2 Cancellation of the call 27
9.3 Data Protection 27
9.4 Confidentiality 28
9.5 Avoidance of conflict of interest during evaluation 28
9.6 Ethics and values 29
9.7 Intellectual property rights 29
9.8 Withdrawal or suspension of participation 29
9.9 Checks, reviews, audits and investigations 29
9.10 Applicable law 30
9.11 Settlement of disputes 30
9.12 Marketing, Communication, Dissemination and Visibility 30
10 About the EIT 31
10.1 EIT and Knowledge and Innovation Community (KIC) relations 31
10.2 Contractual framework between the EIT and the KICs 31
11 About EIT Health 33
11.1 Vision and mission 33
11.2 Strategic Objectives 33
12 Overview of Participating KICs 34
12.1 EIT Community Regional Innovation & Internationalisation Cluster and EIT Regional Innovation Booster Poland 34
12.2 Overview of EIT Health 34
12.3 Overview of EIT Digital / 28DIGITAL 34
12.4 Overview of EIT Food 34
12.5 Overview of EIT InnoEnergy 34
12.6 Overview of EIT Raw Materials 35
12.7 Overview of EIT Urban Mobility 35
12.8 Overview of EIT Culture & Creativity 35

Change Log

Version	Date	Description
1	25/11/2026	Initial release of the Call Document.

Abbreviations

EIT	European Institute of Innovation and Technology
EIT RIB	EIT Regional Innovation Booster
KIC	Knowledge and Innovation Community
EIT SIA	EIT Strategic Innovation Agenda
PA	Partnership Agreement
HE MGA	Horizon Europe Model Grant Agreement
KIC SA	KIC Strategic Agenda
BP	Business Plan
RI&I Cluster	EIT Community Regional Innovation and Internationalisation Cluster
EIT KPIs	Set of Key Performance Indicators (KPIs) defined by the EIT that reflect the EIT operational objectives for education, entrepreneurship, and innovation. These KPIs are used to measure how effectively a KIC meets the objectives of the EIT.
KAVA	KIC-added value activity
FSTP	Financial support to third parties
WP	Work Plan
FTE	Full-Time Equivalent

Definitions

Applicant	A for-profit SME registered in Poland that submits a complete application as a single legal entity.
Application	The complete submission made through the EIT Health Smart Simple application platform, including mandatory supporting documentation.
Call	This EIT RIB Poland 2026/27 Call Document and the documents referenced in it.
EIT	European Institute of Innovation and Technology
KIC	EIT Knowledge and Innovation Communities (KICs) are Europe-wide networks focused on addressing specific societal challenges, ranging from sustainable energy and climate change to healthy food and green transport.
KIC Buddy	A domain- and/or market-matched expert or representative from the relevant KIC ecosystem who supports a selected venture through a focused minimum 20-hour market-intelligence engagement.
MoC KIC	A KIC participating in EIT RIB through a Memorandum of Cooperation with the EIT Community RI&I Cluster, rather than as a core member of the Cluster.
Participant	An Applicant selected to progress beyond remote evaluation and invited to participate in the EIT RIB Poland programme.
Programme Lead	EIT Health is the programme lead acting on behalf of the EIT Community RI&I Cluster for the coordination of this Call and programme delivery.

Call Fact Sheet

Call publication	25 November 2026
Deadline for applications	27 January 2027, 16.00 CET
Evaluation timeline	• Evaluation of proposals start: 11 February 2027 • Notification of final outcome: 14 March 2027
Project implementation timeline	• Signature of agreements: 26 April 2027 • Programme start: 26 April 2027 • Programme end: 07 July 2027
Scope	• Mature, high-potential Polish ventures targeting Germany, Spain or the Nordic countries and requiring cross-KIC market, technology and investment-readiness support.
Solution eligibility[1]	• TRL 7 or above, a credible thematic fit with at least one participating EIT KIC, and all eligibility conditions satisfied.
List of call documents	• Call Document; • Application form, available on the application platform here. • FAQ available here; • Participation agreement template available here
How to apply	• **Step 1:** register your organisation in the EU Funding & tender opportunities portal to obtain the nine-digit Participant Identification Code (PIC number). If you do not know if your organisation already has a PIC number, you can verify directly on the EU Portal (click here) whether your organisation is already registered. • **Step 2:** apply to the call via EIT Health's application platform here.
Events	• **Call introduction webinar**: 02 December 2026**.** Click here to register.
Contact	calls@eithealth.eu Use the subject line: "EIT RIB Poland 2026".

[1] Please see the full scope of eligibility conditions listed in chapter three; Conditions to Receive Funding.

1 Introduction

EIT Health is a Knowledge and Innovation Community (KIC) of the European Institute of Innovation and Technology (EIT), an EU body operating under the Horizon Europe framework. EIT RIB Poland 2026/27 is coordinated by EIT Health on behalf of the EIT Community Regional Innovation and Internationalisation (RI&I) Cluster and is designed to mobilise cross-KIC expertise for high-potential ventures in Poland.

EIT Health encourages the participation of entities from the EIT Regional Innovation Scheme (EIT RIS Regions) with the goal of improving the Knowledge Triangle integration and the innovation capacity of local ecosystems in RIS countries and regions. To read more about the EIT RIS Scheme please click here.

This Call contributes to the EIT Regional Innovation Scheme objective of strengthening innovation capacity and knowledge-triangle integration in eligible regional ecosystems. It is designed to help mature Polish ventures access relevant EIT Community expertise and connect more effectively to established KIC Business Creation, market-access and investment processes. You can read more about the EIT Regional Innovation Scheme here.

The European Commission is committed to promoting gender equality in innovation and technology. EIT, as a body of the European Union and an integral part of Horizon Europe, and EIT Health share the EIT KIC gender diversity value statement. Consequently, the gender requirements in Horizon Europe are of significant importance for all EIT Health supported and funded activities, including the ones in this call for proposals.

2 Description of the Call Objectives and Scope

2.1 Programme Description

The EIT Regional Innovation Booster Poland 2026/27 is a coaching programme targeted at promising Polish start-ups. Up to 25 successful applicants will receive at least 22 hours of coaching and mentoring services to support participants prepare for expansion into Spanish, German, or Nordic markets. This call is for acceptance onto the coaching and mentoring programme only. No funding is available to applicants for this programme. Coaching and mentoring will be provided fully online.

Mentoring and coaching sessions will be broken down into two parts; with support from an assigned mentor, the first two hours will be used for programme planning. Applicants will be expected to create a plan detailing on how they wish to spend the remaining hours of mentoring support. The output for this first part should be a mentoring plan that decides which market (Spanish, German, or Nordic market) the entity wishes to be mentored on, lists the areas of support required, the questions each entity wishes to ask their expert mentor, and the amount of mentoring time to be spent on each area.

The second part of the programme will be the delivery of the mentoring support against this plan. An expert mentor in launching innovations in Spanish, German, or Nordic markets will be assigned to each team according to the target market selected by the participant.

Each selected venture may nominate up to two representatives to participate in the programme. At least one participant must be the CEO, or senior management authorised to take decisions on the venture's market-entry priorities. The support is provided to the entity as a whole. The CEO / authorised senior manager must participate in the first two hours of mentoring to create the mentoring plan.

Mentoring will be delivered according to the programme timeline in Section 4.1 and will be tailored to the venture's agreed needs, target market and suitable KIC Buddy match. The engagement may include market intelligence, customer or partner mapping, market-entry preparation, technology or sector input, and practical guidance on readiness for relevant KIC processes. Following completion of the programme, participants will receive feedback upon completion of the programme on the potential follow-up support opportunities available to them at the time offered by each relevant KIC.

Alongside mentoring, selected ventures' pitch decks will be forwarded to relevant KIC investment teams, subject to the consent provided in the Application Form and the Call's confidentiality and data-protection provisions. The receiving KIC may invite a venture to a separate investment call or other support opportunity under its own procedures. Forwarding a pitch deck does not guarantee review, feedback, funding or investment.

2.1.1 Project deliverables

The following deliverables in the below table are required as part of the programme and must be delivered on time.

#	Deliverable	Definition	Due (in months)
1	**Mentoring Planning Action Plan**	A concise, practical plan prepared after the two-hour mentoring planning session. It records the startup's current position, chosen target market, priority questions, agreed mentoring objectives, key workstreams, desired outputs and proposed allocation of the subsequent RIB Poland Buddy hours.	M0-1
2	**Communications and dissemination plan**	A plan on the communications and outreach activities participants with employ whilst participating in this programme. See paragraph 9.12 on Marketing, Communication, Dissemination and Visibility for more details.	M0-1
3	**Mentoring record and report**	A short record of the minimum 20-hour mentoring sessions, covering the topics addressed, key insights, and conclusions, actions, and next steps. This report must cover the full programme period.	M2 - 4
4	**Final Action and Market-Entry Summary**	An updated Action Plan that is adjusted following the mentoring sessions. It will detail the next steps, possible market-entry steps, and relevant non-binding opportunities for further engagement where available. This should be submitted within 10 working days after completion of mentoring sessions.	M5 - 6

2.1.2 Key Performance Indicators (KPIs)

The programme is designed to help ventures clarify and plan how they will access and launch their product into the Spanish, German, or Nordic markets. Selected ventures will receive hands-on help with international expansion and customer acquisition, gain greater visibility, and establish new connections in European markets.

As an initiative from the European Institute of Innovation and Technology (EIT) involving several different Knowledge and Innovation Communities (KICs), participants will also get the opportunity to learn about the opportunities on offer from different KICs and their innovation ecosystems.

EIT KICS will monitor programme delivery. Applicants are not required to submit an individual Key Performance Indicator (KPI) plan. However, selected ventures may be asked to provide information to facilitate programme delivery and impact monitoring. The Key Performance Indicators (KPIs) this programme targets are detailed in the table below.

KPI	Definition, target, and timeline
EIT HE 03.2: EIT RIS Start-ups/scale-ups supported	Number of start-ups and scale-ups registered in an EIT RIS country supported by KICs for at least two months in year N.
EIT HE 06.2: Investment attracted by KIC supported EIT RIS start-ups/scale-ups	Total EUR amount of private and public capital attracted within year N by supported start-ups/scale-ups established in EIT RIS countries that have received KIC business-creation services support of at least two months, within a maximum of three years following the last received KIC KAVA support activity.
EIT HE 13.2: EIT RIS Success stories	This programme aims to capture at least one success story on the impact this programme has had on participants. A selected venture is not automatically a success story; the story must be substantiated and developed in line with applicable reporting and communications requirements.
XXIC-RI101: Impact stories featuring testimonials	Impact stories featuring testimonials produced per Initiative per year in line with EIT branding and communications requirements and showcased on website.

3 Call Criteria

Following the submission deadline, EIT Health will perform admissibility, eligibility, exclusion and selection checks. Only complete applications that meet all admissibility and eligibility conditions and are not subject to exclusion can proceed to Remote Evaluation.

3.1 Application Admissibility

Only proposals satisfying all the admissibility criteria below shall pass on to the eligibility criteria assessment stage.

- Applications must be submitted before the call deadline on 27 January 2027, at 16.00 CET via the EIT Health Smart Simple application platform. Any proposals submitted after the deadline will be inadmissible.
- Applications must be submitted using the application platform. Applications submitted through other means will be inadmissible.
- Applications must use a valid Participant Identification Code (PIC code).
    - To obtain a PIC code, register your organisation in the EU Funding & tender opportunities portal to obtain the nine-digit Participant Identification Code (PIC number). If you do not know if your organisation already has a PIC Code, you can verify directly on the EU Portal (click here) whether your organisation is already registered.
- All upload templates provided in the application platform must be used and unaltered. Uploads that do not use the templates where provided will be inadmissible.
- All mandatory fields in the Application Form are completed in English and all mandatory supporting documentation is uploaded in the required format.
- Only one application is submitted per company.

3.2 Application Eligibility Conditions

Only proposals satisfying all the eligibility criteria below shall pass on to the evaluation stage.

3.2.1 Entities eligible for support

To be eligible to participate in the RIB Poland Programme, entities must:

- be a single legally registered, for-profit micro, small or medium-sized enterprise established in Poland.
- Meet the EU definition of a micro, small, or medium enterprise.[2]
- Have at least one Full-Time Equivalents (FTEs) on the payroll.
- Have a Chief Executive Officer (CEO) working full time for the company.

[2] To see if your organisation meets this definition please use this tool - SME Self-assessment | EU Funding & Tenders Portal

- Have secured at least EUR 150,000 in prior private investment through equity, convertible loans or other dilutive sources, grants do not count.
- Hold the ownership or exclusive commercialisation rights necessary to develop and market the proposed solution.
- Propose a solution at TRL 7 or above.
- Demonstrate credible thematic relevance to at least one participating EIT KIC.
- Demonstrate a credible rationale for entry into Germany, Spain or the Nordic countries.

Applicants must submit all evidence and information required in the Application Form. An applicant must satisfy all eligibility conditions to progress to Remote Evaluation.

3.2.2 EIT Knowledge Innovation Community (EIT KIC) fit

The solution of the applying entity must address an unmet need that aligns with at least one of the areas of focus of the participating EIT KICs. A solution may be relevant to more than one EIT KIC. The table below provides a non-exhaustive list and description of the EIT KICS and the areas of focus. Please refer to each of the participating KIC websites for more detail.

KIC Name	Policy area	Description
EIT Health	**Health innovation**	Supports innovation addressing unmet health needs, including health and care delivery, digital health, medical technologies, prevention, diagnostics, therapies, care pathways and health-system innovation
EIT Food	**Food and agrifood innovation**	Supports innovation for healthier, more sustainable and resilient food systems, including agrifood technologies, food production and supply chains, nutrition, food safety, resilient agriculture, protein diversification and food-system transition.
28Digital (formerly EIT Digital)	**Digital innovation**	Supports digital innovation, startup and scaleup development, digital skills, research-to-market activity, AI, data, software, connectivity, cybersecurity and related digital technologies.
InnoEnergy	**Clean technology and energy transition**	Supports clean-technology innovation and the energy transition, including renewable energy, storage, electrification, energy efficiency, industrial decarbonisation, energy systems and related value chains.
EIT Raw Materials	**Raw materials and circularity**	Supports innovation across the raw-materials value chain, including exploration, mining, processing, recycling, circular economy, advanced materials, strategic raw materials and sustainable resource use.
EIT Urban Mobility	**Sustainable urban mobility**	Supports innovation that decarbonises mobility and makes urban spaces more liveable, including public and shared transport, logistics, mobility services, transport systems, infrastructure and urban mobility technologies
EIT Culture & Creativity	**Cultural and creative sectors and industries**	Supports innovation in Europe's cultural and creative sectors and industries, including creative technologies, media and audiovisual, architecture, design, fashion, gaming, cultural heritage and creative entrepreneurship.

Climate KIC	**Climate innovation, mitigation and adaptation**	Supports innovation for climate change mitigation, adaptation and resilience, including decarbonisation, climate-neutral cities, circular economy and sustainable systems transformation.

3.2.3 Private investment history

Applying entities must have secured at least 150,000 EUR in private investment through equity, convertible loans or other dilutive sources. Grants do not count. A fully executed investment agreement must be uploaded to the application platform for review.

3.2.4 Intellectual property rights

The applying entity must hold full ownership or exclusive commercialisation rights over the intellectual property of the proposed solution.

3.2.5 Technology Readiness Level

Solutions must be at least Technology Readiness Level (TRL) 7. For the purposes of eligibility, applicants will be asked to self-assess their TRL during the application process. However, the TRL level of the solution will also be evaluated during the evaluation process. Applicants may be marked down or excluded should evaluators disagree with the TRL stated on the application. To find out more about TRL levels, please see here.

3.2.6 Target markets

Entities must be targeting entry into either Germany, Spain or the Nordic countries as its intended RIB Poland target market and provides a credible rationale and market-entry needs.

3.3 EU Restrictions on Participation

Applicants subject to EU restrictive measures are not eligible to participate in the Call. This includes entities subject to measures adopted under Article 29 TEU, Article 215 TFEU or Article 75 TFEU, and any entity whose participation would be prohibited by the applicable EU legal framework.

Legal entities established in Russia, Belarus or non-government-controlled territories of Ukraine are not eligible to participate. This also applies, where relevant, to entities established outside Russia but directly or indirectly owned more than 50% by a legal person, entity or body established in Russia, in accordance with applicable EU restrictive measures. EIT Health may apply additional restrictions where required by law or the applicable EIT framework

3.3.1 EU restrictive measures

Entities subject to EU restrictive measures under Article 29 of the Treaty on the European Union (TEU) and Article 215 of the Treaty on the Functioning of the EU (TFEU)[3] as well as Article 75 TFEU[4], are not eligible to participate in any capacity, including as beneficiaries, affiliated entities, associated partners, third parties giving in-kind contributions, subcontractors or recipients of financial support to third parties (if any).

Special rules also apply to entities covered by Commission Guidelines No 2013/C 205/0522[5].

3.3.2 Legal entities established in Russia, Belarus, or in non-government-controlled territories of Ukraine

Given the illegal invasion of Ukraine by Russia and the involvement of Belarus, there is currently no appropriate context allowing the implementation of the actions foreseen in this programme with legal entities established in Russia, Belarus, or in non-government-controlled territories of Ukraine. Therefore, even where such entities are not subject to EU restrictive measures, such legal entities are not eligible to participate in any capacity. This includes participation as beneficiaries, affiliated entities, associated partners, third parties giving in-kind contributions, subcontractors or recipients of financial support to third parties (if any). Exceptions may be granted on a case-by-case basis for justified reasons.

With specific regard to measures addressed to Russia, following the adoption of the Council Regulation (EU) 2024/1745 of 24 June 2024[6] (amending Council Regulation (EU) No 833/2014 of 31 July 2014) concerning restrictive measures in view of Russia's actions destabilising the situation in Ukraine, legal entities established outside Russia but whose proprietary rights are directly or indirectly owned for more than 50% by a legal person, entity or body established in Russia are also not eligible to participate in any capacity.

3.3.3 Restrictions for the protection of European communication networks

The protection of European communication networks has been identified as an important security interest of the Union and its Member States[7]. For further information, please refer to the Horizon Europe, Work Programme 2025, General Annexes, B – Eligibility on page 14[8].

[3] Please note that the EU Official Journal contains the official list and, in case of conflict, its content prevails over that of the EU Sanctions Map
[4] Please note that the EU Official Journal contains the official list and, in case of conflict, its content prevails over that of the EU Sanctions Map
[5] Commission guidelines No 2013/C 205/05 on the eligibility of Israeli entities and their activities in the territories occupied by Israel since June 1967 for grants, prizes and financial instruments funded by the EU from 2014 onwards (OJEU C 205 of 19.07.2013, pp. 9-11)
[6] OJ L 229, 31.7.2014, p. 1–11
[7] European Council conclusions of 1 and 2 October 2020 (EUCO 13/20), point 11; Council Conclusions on the significance of 5G to the European Economy and the need to mitigate security risks linked to 5G, 14517/19.
[8] https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2025/wp-14-general-annexes_horizon-2025_en.pdf

3.4 Applicant Exclusion Criteria

An Applicant may be excluded from the Call where it is in bankruptcy, insolvency, winding-up or a comparable situation; has materially breached tax or social-security obligations; has committed grave professional misconduct, fraud, corruption, money laundering, terrorism-related offences, trafficking or child labour; has materially misrepresented information; has committed serious deficiencies under a relevant EU agreement; or has attempted to improperly influence the Call process, access confidential information or distort competition.

The Applicant confirms through submission that it is not in an exclusion situation and must promptly notify the Programme Lead if this changes. EIT Health may request a declaration of honour or supporting evidence where necessary to verify eligibility, compliance or the integrity of the process.

Applicants will be excluded from participation in the Call and from the award if they are in one of the situations referred to in Article 138(1) of the EU Financial Regulation. Applicants may not participate in this call that are subject to EU administrative sanctions (i.e. exclusion) or are in one of the following exclusion situations that bar them from receiving EU grants:

- bankruptcy, winding up, affairs administered by the courts, arrangement with creditors, suspended business activities or other similar procedures (including procedures for persons with unlimited liability for the applicant's debts);
- they are in breach of social security or tax obligations (including if done by persons with unlimited liability for the applicant's debts);
- they are guilty of grave professional misconduct (including if done by persons having powers of representation, decision-making or control, beneficial owners or persons who are essential for the award/implementation of the grant);
- they are guilty of fraud, corruption, having links to a criminal organisation, money laundering, terrorism-related crimes (including terrorism financing), child labour or human trafficking (including if done by persons having powers of representation, decision-making or control, beneficial owners or persons who are essential for the award/implementation of the grant);
- they have shown significant deficiencies in complying with their main obligations under an EU procurement contract, grant agreement, prize, expert contract, or similar (including if done by persons having powers of representation, decision-making or control, beneficial owners or persons who are essential for the award/implementation of the grant);
- they are guilty of irregularities within the meaning of Article 1(2) of Regulation No 2988/9534 (including if done by persons having powers of representation, decision making or control, beneficial owners or persons who are essential for the award/implementation of the grant); or
- they have created under a different jurisdiction an entity with the intent to circumvent fiscal, social or other legal obligations in the country of origin or created another entity with this purpose (including if done by persons having powers of representation, decision-making or control, beneficial owners or persons who are essential for the award/implementation of the grant).
- Have misrepresented the information required as a condition for participating in the procedure or have failed to supply that information; or,

- were previously involved in the preparation of documents used in the award procedure where this entails a breach of the principle of equality of treatment, including distortion of competition, that cannot be remedied otherwise.

As evidence, the applicants (i.e. the coordinator and all the proposed partners participating in the applicant consortium) will have to submit a declaration of honour on exclusion criteria and absence of conflict of interest. Failure to provide adequate documentation may result in the exclusion of the applicants concerned.

3.5 Integrity, conduct and conflict of interest on the part of applicants and participants

Applicants, participants, evaluators, experts and programme representatives are expected to act professionally, respectfully and in accordance with applicable law. An Applicant or Participant may be excluded where an exclusion situation applies or where conduct undermines the integrity, fairness, safety or effective delivery of the Call or Programme. By applying to this call applicants and participants agree to:

- Treat all participants, staff, evaluators, experts and stakeholders with dignity and respect.
- Provide truthful, complete and timely information and promptly correct material inaccuracies.
- Protect confidential information and intellectual property and use information only for authorised purposes.
- Disclose actual, potential or perceived conflicts of interest without delay.
- Comply with applicable ethical, legal, safety, anti-fraud and data-protection requirements.
- Refrain from harassment, discrimination, abusive conduct, fraud, corruption, misuse of information or attempts to improperly influence the Call process.

3.6 Contracting Requirements for Successful Applicants

Selected applicants will be required to sign a Participation Agreement before beginning the programme. You can see a template of the participation agreement here.

4 Application Process

All application materials must be submitted via the EIT Health Smart Simple application platform. Applicants are strongly advised to familiarise themselves with Smart Simple and to begin the application two weeks before the deadline. Due to the volume of enquiries, technical support with applications in the final week before the application deadline cannot be guaranteed.

Applicants are responsible for ensuring that links, uploads and documents are accessible and complete. The Application Form specifies the required supporting documentation, including the prior-investment agreement, cap table, P&L statement, financial projections, pitch video and pitch deck.

4.1 Call and Programme Timeline

Milestone	Date	Description
Call opening	**25 November 2026**	Publication of the Call Document and opening of the Smart Simple application process.
Call introduction webinar	**02 December 2026**	Overview of the RIB Poland model, eligibility conditions and Smart Simple application process.
Call close	**27 January 2027, 16:00 CET**	Deadline for complete applications through Smart Simple.
Eligibility check	**27 January - 10 February 2027**	Admissibility, eligibility and exclusion review.
Eligibility check outcome notification	**10 February 2027**	Notification of the outcome of the eligibility check.
Remote Evaluation	**11 February - 11 March 2027**	Assessment of eligible applications against the published scorecard.
Final Outcome Notification	**14 March 2027**	Communication of final outcome of application evaluation.
Stand Still period	**24 March – 24 April 2027**	Mandatory stand still period
Contracting and preparation	**26 April 2027**	Signature of the Participation Agreement, confirmation of named startup representatives and scheduling of Mentoring Planning sessions.

Milestone	Date	Description
Programme Kick Off Meeting	**26 April 2027**	Kick off meeting for all successful participants to introduce the programme and answer questions.
Mentoring Planning sessions and Action Plans	**26 April to 07 May 2027**	Each selected startup completes the two-hour Mentoring Planning session and prepares an Action Plan for the RIB Poland Buddy mentoring.
Mentoring sessions	**17 May – 09 July 2027**	Each selected startup receives at least 20 hours of tailored mentoring, guided by its mentoring planning Action Plan.

4.2 Use of Artificial Intelligence

Applicants may use generative-AI tools to assist in preparing their application, but remain fully responsible for the accuracy, originality, relevance and completeness of all content submitted. Applicants must critically review AI outputs, verify any references or factual statements, avoid plagiarism, protect confidential and personal data, and ensure that they hold the rights necessary to use any submitted material. Applicants should disclose AI use where this is material to understanding the application or the underlying solution.

All AI-generated content must be handled with caution, responsibility, and full transparency. Below are EIT Health's guidelines that applicants should consider when using generative AI tools to build a proposal:

- **Review & validate:** Critically check AI output for factual accuracy, relevance, and alignment with the call's objectives.
- **Verify citations:** Cross-check any references suggested by AI; remove or correct any that are fabricated or incorrect.
- **Ensure originality:** AI may mirror existing sources—applicants must avoid plagiarism by properly attributing all material.
- **Disclose usage when advisable:** Clearly state which AI tools were used and how.
- **Respect IP & privacy:** Do not include copyrighted or proprietary material without authorization; review AI platform terms and avoid submitting confidential or sensitive data to AI tools, unless data protection standards (e.g. GDPR) are met.

Applicants remain entirely accountable for every part of their proposal, including AI-produced text.

5 Evaluation Procedure

5.1 Evaluation Criteria & Scoring

Eligible applications will be assessed against the four criteria set out below.

For each evaluator, the score awarded for each criterion will be multiplied by the relevant weight and converted to a score out of 100. The final application score will be the mean of the valid total scores awarded by the evaluators, as described in Section 5.2. Applications must meet the minimum score and ranking requirements stated in Sections 5.2 and 5.3 to be selected.

Evaluation Criteria	Sub Criteria	Description
Excellence **Weight – 25%**	Alignment with the call	The proposal demonstrates a clear understanding of the call and the application and solution is fully aligned with the scope and requirements of the Call.
	Solution clarity	The innovation is clearly described
	Unmet need	The solution addresses a clear unmet need that is well evidenced.
	Track record and sector experience	The application demonstrates a proven track record in designing and delivering comparable startup acceleration, open innovation, or corporate-startup collaboration programmes, including experience supporting startups at different stages of product and market maturity.
	Solution novelty	The innovation is novel and goes beyond what is already offered on the market.
	Maturity	The application's assessment of the innovation maturity is accurate and credible
	Scientific quality	The scientific evidence supporting the innovation is robust
	Regulatory	The application demonstrates a good understanding of the regulatory requirements to enter its selected market.
	Gender	The application includes a well-reasoned explanation of how gender has been accounted for in the innovation and/or in the start-up.

Evaluation Criteria	Sub Criteria	Description
Impact **Weight – 20%**	Outputs, outcomes, and impacts	The proposal demonstrates a logical pathway from its outputs, to outcomes, to desired impact through entry into a new market.
	Growth potential	The innovation demonstrates a strong potential to scale beyond its target market.
	Corporate-startup collaboration and pilot preparation	The applicant demonstrates the capacity to facilitate productive collaboration between startups and corporate challenge sponsors and to support the preparation of credible Pilot Action Plans.
Quality and Efficiency of Implementation **Weight – 10%**	Capacity and capability	The start-up's leadership team demonstrates the capability and capacity to enter a new market successfully.
	Programme need	The application demonstrates a strong case for mentoring and is clear on its priorities for the mentoring programme.
KIC Portfolio Strategic Fit and Compliance with the Financial Sustainability Principles **Weight – 45%**	Intellectual property	The intellectual property strategy, ownership and governance of the start-up is robust and conducive to commercial operations.
	Commercialisation model	The start-up has a strong commercialisation model for its innovation.
	Commercialisation progress	The application demonstrates, with evidence, the commercial success achieved to date.
	Commercial potential	The application has a strong rationale for the market it has chosen to enter next and shows awareness of the market and its barriers.
	Financial health and growth potential	The applications financial health is strong and shows promise for continued financial growth

Each criterion will be scored on a scale from 0 to 5. A score of 0 means that the proposal fails to address the criterion or provides insufficient evidence. A score of 5 means that it addresses the criterion comprehensively, with no material shortcomings. Scores may be awarded in 0.5 increments. The detailed scorecard will set out the scoring descriptors and the criterion-specific evaluator questions.

Score	Rating	Description
0	Not met	The application does not address the criterion and provides insufficient evidence to demonstrate that it is met.
1	Poor	The criterion is inadequately addressed, or there are serious weaknesses
2	Fair	Application broadly addresses the criterion but there are significant weaknesses
3	Good	Application addresses the criterion well, but there are several shortcomings.
4	Very good	Application addresses the criterion very well, with just a small number of shortcomings
5	Excellent	Application addresses all the criterion well, and any shortcomings are minor.

5.2 Evaluation Process

1. Admissibility and eligibility, exclusion and selection stages

EIT Health performs an initial check of application completeness, admissibility, eligibility and exclusion criteria. Applications that do not meet all applicable requirements do not progress to Remote Evaluation. EIT Health may request clarification only where this is compatible with equal treatment and does not materially change the application. See chapter 3 for call conditions.

2. Remote Evaluation

Each eligible application is reviewed by two external evaluators and one EIT KIC specialist. Final scores are an average of all evaluators scores. Applications must score at least 70 / 100 to be considered for admission on to the RIB Poland programme. Application scores will be ranked from highest to lowest, and up to the top 25 highest-ranked applications will be invited to the programme.

5.3 Evaluation methodology

5.3.1 Remote evaluation methodology

Each application will be reviewed by a panel of two external experts and one EIT KIC specialist in accordance with the evaluation criteria (paragraph 5.1). Each application will receive a single score and feedback on the application from each panel member who reviewed the application. The final

application score is the arithmetic mean of the three complete evaluator scores, each calculated out of 100.

Applications will then be ranked from highest scoring to lowest scoring. The top 25 applications that score 70 / 100 or more will then be selected to participate in the programme and invited to sign the participation agreement.

Applicants that score 70 or above but are not ranked in the top 25 may be contacted and invited to join the programme in the event that one of the selected applicants does not sign the Participation Agreement.

5.4 Communication of evaluation results to applicants

5.4.1 Communication of evaluation results

All evaluated applicants will receive their overall score and feedback from each panel member. Applicants that do not progress to Remote Evaluation will be informed of the outcome of the admissibility and eligibility checks. It is important that all emails with the @eithealth.eu domain are added to the safe senders list for all consortium members so that critical emails do not get sent to applicants' spam folder.

Applicants may request further clarification regarding the evaluation result via email. EIT Health will aim to reply to such requests within 15 days. Where this is not possible, EIT Health will inform the applicant requesting clarification with an estimated response time.

5.4.2 Requirements for selected proposals

If the proposal is selected, subsequent communications may include a set of recommendations or conditions as a result of the outcome of the evaluation. These requirements may not entail a substantial modification of the proposal.

Such communications will establish a clear and non-negotiable deadline for the submission of the adjusted proposals.

Should all conditions be met within the established deadline, EIT Health will initiate the participation agreement preparation process/onboarding (e.g. legal entity validation, signature of Declaration of honour, if not yet provided, financial capacity check, if relevant).

If the applicant fails to comply with the provided recommendations/conditions or does not respond in the time allocated, EIT Health reserves the right to withdraw the conditional notification. Should this occur, EIT Health may decide to contact the following application in the final ranking list.

5.5 Standstill Period

Following final outcome notification, a 30-day standstill period will begin, lasting from 24 March to 24 April 2027. During this time no contracts will be signed, however this time may be used to review and prepare participation agreements for signature from 26 April 2027.

5.6 Publication of Call Results

EIT Health may make available via its website, information on the call results and the recipients of funds from this call.

The following information shall be published, having due regard for the requirements of confidentiality and security, in particular the protection of personal data:

- the recipient's full legal name and the country where it is established;
- the amount committed and, in case of a commitment with multiple recipients, the breakdown of this amount per recipient where available;
- subject of grant or contract.

6 Project Monitoring

6.1 Monitoring During and After Participation

EIT Health will monitor delivery, quality, learning and impact on a proportionate basis. Monitoring does not constitute grant cost reporting.

At programme start, EIT Health will confirm the Participation Agreement, named startup representatives, attendance at the programme kick-off and the two mentoring action plan session schedule.

After the initial two-hour mentoring planning session, each startup will submit a Mentoring Action Plan. EIT Health will record the chosen target market, priority questions, agreed mentoring objectives and RIB Poland Buddy matching requirements.

During mentoring sessions: EIT Health will record the mentoring sessions delivered and may conduct a short progress check-in where needed to confirm that delivery remains aligned with the Action Plan and to identify material issues.

At programme completion: each startup will provide its Final Action and Market-Entry Summary and participant feedback. The RIB Poland Buddy mentoring record will confirm the support delivered, key insights and agreed next actions.

Six months after programme completion: EIT Health may request a short, non-confidential outcome update on progress against the Action Plan, market or partner engagement, additional support received and commercial, market-entry or investment outcomes where available. Further follow-up may take place on a reasonable basis, in accordance with the Participation Agreement and applicable data-protection requirements.

7 Grounds for Appeal and Appeal Procedure

Applicants may appeal the outcome of their application of their own proposal in line with the EIT Health Appeals procedure. The only grounds for appeal are as follows:

- Process errors.
- Technical problems beyond the control of applicants (e.g. the technical failure of the electronic submission system).
- Human/technical errors made by EIT Health staff.
- If you consider that you have been adversely affected by a particular decision not following EIT Health's Code of Conduct.

What does NOT constitute grounds for an appeal:

- Scores awarded in the course of the proposal evaluation process (unless these go against our Code of Conduct).

7.1 Appeals Procedure

- Applicants should send their appeals in writing to appeals@eithealth.eu as soon as they identify an error, but no later than 21 days after the error occurred.
- EIT Health assesses the claim and delivers a first response
- If there are grounds for appeal, EIT Health will attempt to remedy the consequences (e.g. if a technical error of EIT Health prevented the submission of a proposal or application, a late submission may still be accepted as eligible)
- The Head of Compliance, and where applicable, Supervisory Board is notified about the matter if:
    - the applicant does not accept a rejection of the appeal, or
    - there are grounds for appeal, but the problem cannot be remedied any more without disrupting the process

8 Where to Get Help

We aim to make the application process as clear and accessible as possible. If you have questions regarding the EIT Regional Innovation Booster Call 2026, please consult the following resources:

8.1 Call Information Webinars

We offer two distinct online sessions to guide applicants:

Session	Purpose	Date & Access
Call Presentation Webinar	Comprehensive introduction to the Call's objectives and scope.	**02 December 2026, 11.30am CET** Register here

8.2 Frequently Asked Questions (FAQ)

A comprehensive Frequently Asked Questions (FAQ) document is available, covering common questions on eligibility, the Lump Sum budget model, budget preparation, and the evaluation process. We recommend consulting this document before submitting your formal application.

- **Access Link:** Access FAQ's here

8.3 Contact for Support

For general administrative queries, questions about the application platform, or technical issues with the submission process, please contact the EIT Health directly:

- **Email:** calls@eithealth.eu – please include the call code: "RIB Poland 2026/27" and your application reference code in the subject line of all correspondence.

9 Other Terms and Conditions

9.1 Acceptance of the call conditions

EIT Health reserves the right to make reasonable amendments and additions to the call conditions. Amendments and additions to the call conditions shall be valid only before the submission deadline, and if made available to all potential applicants at the same time via this call document and any relevant call documents.

EIT Health may declare the call unsuccessful in the case where zero applications are received, if the applications do not meet the admissibility, eligibility, exclusion and selection criteria, or if none of the applications reach the score thresholds laid down in this call text.

By submitting the application form, the applicant agrees to the present call conditions. Applicants agree that they have no legal entitlement to funding.

9.2 Cancellation of the call

EIT Health reserves the right to cancel the call at any time before the signature of the Participation Agreement(s) without the obligation to compensate applicants, in particular where its objectives can no longer be met, provided that the applicants are informed in a transparent manner in writing as follows:

- if the cancellation takes place before that award: on the call page of https://eithealth.eu/
- if the cancellation takes place following the communication of the results to the applicants, during the standstill period, or anytime before the signature of the Participation Agreement: in writing directly to the selected applicants.

9.3 Data Protection

EIT Health ensures that any processing of personal data shall be performed in accordance with Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016, on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and in accordance with Directive 95/46/EC (General Data Protection Regulation). As a data subject, you have the right of access, the right to rectification, the right to erasure, the right to restrict processing, the right to data portability, the right to object, and the right not to be subject to a decision based solely on automated processing. If you have a question about personal data processing or want to exercise your data subject rights, you can contact our Data Protection Officer at DataPrivacy@eithealth.eu.

The collected personal data will be used solely for the evaluation of the applications and the conduct of the call process. The data controller is EIT Health.

Personal data will be deleted five years after the announcement of the results of the call in case of unsuccessful applications and seven years for successful applicants.

By submitting your application to this call, you consent that EIT Health will collect, transfer, process, store, and delete your data in accordance with the aforementioned conditions.

For more information on the processing of your personal data as part of an application to this call, please consult the Legal notice and Terms of use of EIT Health's online application management platform. You can also read EIT Health's online privacy statement at: https://eithealth.eu/privacy-policy/.

9.4 Confidentiality

EIT Health undertakes to use any confidential information shared by the applicants solely for the purposes of the evaluation process.

Confidential information shall mean data and/or information (in any form) that is proprietary to, or possessed by, the applicants and not generally known to the public, or that has not yet been revealed whether in tangible or intangible form, that is identified as confidential in writing or when disclosed orally.

Confidential information included in the application form must be expressly labelled by the applicant as such in the form. As regards confidential information expressly labelled as such in the call process, EIT Health undertakes to (i) not disclose them in any way and any form, without the prior written authorization of the applicant; and (ii) not to use them for purposes other than those strictly necessary for participation in the call.

Confidential information may be shared among participating KICs, EIT Health and its subsidiaries (e.g. KIC Co-Location Centres) solely for the purposes of the call process. EIT Health undertakes to impose this confidentiality obligation on its employees and the employees of its subsidiaries and its collaborators, as well as on independent experts and all subjects who, by virtue of participating in the conduct of the call, including as members of the Evaluation Committee, may have access to such confidential data and information.

The applicants agree that data and information regarding the selected projects' implementation (e.g. success stories) not labelled as confidential may be disclosed in connection with the activities of EIT Health.

9.5 Avoidance of conflict of interest during evaluation

EIT Health is committed to ensure the avoidance of conflict of interest (regarding all actors) and comply with the principles of transparency, non-discrimination and sound financial management.

Measures to avoid potential Conflict of Interest or unequal treatment of applicants are ensured including through appropriate conflict of interest declaration and assessment process, established written communication channels and independent and fair complaints/redress procedures.

In case an applicant becomes aware of a potential conflict of interest affecting the conduct of the call process, it shall notify the EIT Health of the conflict of interest without any delay.

9.6 Ethics and values

The proposal must comply with:

- ethical principles (including the highest standards of research integrity); and,
- applicable EU, international and national law, including the Charter of Fundamental Rights of the European Union and the European Convention for the Protection of Human Rights and Fundamental Freedoms and its Supplementary Protocols.

No financial support/ funding can be granted, within or outside the EU, for activities that are prohibited in all Member States. No financial support/ funding can be granted in a Member State for an activity which is forbidden in that Member State.

9.7 Intellectual property rights

Applicants retain full and exclusive ownership of their prior information and intellectual property rights. By submitting their application, applicants confirm that they own or lawfully hold, and have secured or will secure in due time, all rights and permissions necessary to use all elements of the innovative product or service included in their application, or that they will take appropriate measures to secure and protect such rights during the project. Applicants agree to indemnify and hold harmless EIT Health, the EIT, and/or any assignee or affiliate from any third-party allegations or claims of intellectual property rights infringement by the product or service of applicants. Applicants shall have the right to further develop, use and license their intellectual property rights for creating, making, marketing, and distributing products, services, and technology.

9.8 Withdrawal or suspension of participation

EIT Health may withdraw an invitation to participate, suspend support or terminate participation in accordance with the final EIT RIB Poland Participation Agreement where: (i) the applicant was or becomes ineligible; (ii) material information in the application was false, misleading or incomplete; (iii) the participant commits a material breach of the Call conditions or Participation Agreement; (iv) the participant engages in serious misconduct, fraud, corruption or conduct that compromises the integrity, fairness, safety or effective delivery of the Call or programme; or (v) the programme can no longer be delivered for reasons outside EIT Health's reasonable control.

The participant will be informed in writing of the reasons for the decision and of any applicable procedure. As RIB Poland does not provide a participant grant under this Call, no recovery of participant funding is foreseen. Any provision concerning recovery of payments would apply only where a separate, formally approved financial support agreement provides for actual payments.

9.9 Checks, reviews, audits and investigations

EIT Health retains the right to initiate checks, reviews and audit on an applicant that has been awarded support, to verify compliance with the requirements of the call conditions and of the legal and contractual framework referred to above.

EIT Health may request any information and data from applicants that have been awarded support for five years after completion for these purposes, as well as in relation to monitoring by the EIT.

In accordance with the Grant Agreement between the EIT and the KIC as well as the Financial Support Agreement, the EIT and/or the Commission, the European Anti-Fraud Office (OLAF), the European Public Prosecutor's Office (EPPO) and the Court of Auditors may carry out checks, reviews, audits and investigations in relation to the call and the implementation of the projects.

9.10 Applicable law

The present call is governed by the applicable European Union legal framework (i.e. in particular the EIT Regulation[9], the EU Financial Regulation[10], the Horizon Europe Regulation[11]), supplemented if necessary by the national law of Belgium.

The applicants agree to observe the obligations outlined in the Partnership Agreement and the Grant Agreement signed between the EIT and EIT Health. Applicants agree to comply with the terms of the Participant Agreement between successful applicants and EIT Health.

9.11 Settlement of disputes

All disputes arising out of or in connection with this Agreement, which cannot be solved amicably, shall be finally settled before the courts of Brussels.

9.12 Marketing, Communication, Dissemination and Visibility

Article 17 of the Horizon Europe Model Grant Agreement requires that beneficiaries must promote the project and its results through strategic, coherent, and effective communications. Any such communications must be factually accurate, and communication materials must acknowledge EU support and display the European flag and funding statement.[12]

Article 17 of the Horizon Europe Model Grant Agreement requires also requires beneficiaries to inform EIT Health as the granting authority before any communication or dissemination activities take place.

[9] Regulation (EU) 2021/819
[10] Regulation (EU, Euratom) 2024/2509
[11] Regulation (EU) 2021/695
[12] For specific materials and content to use please see Article 17 of the Horizon Europe General Model Grant Agreement - general-mga_horizon-euratom_en.pdf

10 About the EIT

The European Institute of Innovation and Technology (EIT) is a European Union body with a legal personality and a wide legal capacity accorded to legal persons under national law. The EIT was created in 2008 by the European Union (EU) to enhance Europe's global competitiveness by fostering collaboration between businesses, research institutions, and higher education organizations.

The EIT is governed by Regulation (EU) 2021/695 (EIT Regulation), which aligns the EIT's mission with the EU's priorities and the objectives of Horizon Europe on evolving research, innovation, economic growth, job creation, global competitiveness, sustainable growth, higher education and entrepreneurship, by means of the Knowledge and Innovation Communities (KICs), which address specific societal challenges and are established and supported by the EIT.

The EIT Strategic Innovation Agenda (SIA) 2021-2027 is aligned with Horizon Europe and lays down the priority fields and the strategy of the EIT for future initiatives, capacity to generate the best innovation added-value, objectives, key actions, mode of operation, expected results, impact, as well as an estimate of the resources needed for the duration of Horizon Europe.

Horizon Europe Regulation

The Horizon Europe Regulation (EU) 2021/695 foresees that the EIT takes part in the implementation of the Horizon Europe Programme in accordance with its strategic objectives for the period 2021 to 2027, as laid down in the Strategic Innovation Agenda of the EIT, and taking into account the strategic planning of Horizon Europe.

10.1 EIT and Knowledge and Innovation Community (KIC) relations

The EIT Regulation defines KICs, such as EIT Health, as large-scale Institutionalised European Partnerships of higher education institutions, research organisations, companies and other stakeholders in the innovation process in the form of a strategic network, regardless of its legal form, based on joint mid- to long-term innovation planning to meet the EIT's challenges and contribute to attaining the objectives established.

According to the EIT Regulation, and without prejudice to the partnership agreements and grant agreements between the EIT and each KIC, the KICs have substantial autonomy to establish their internal organisation and composition, as well as their agenda and working methods, provided that they result in progress towards achieving the objectives of the EIT and the KICs, taking into account the strategic planning of Horizon Europe and the strategic direction of the EIT set out in the SIA and by the Governing Board.

10.2 Contractual framework between the EIT and the KICs

The long-term relations between the EIT and each KIC are based on a seven-year Partnership Agreement (PA)[13] laying down the general terms and conditions under which the KIC operates as an Institutionalised European Partnership. Subject to positive performance, interim review and outcome of

[13] Model Partnership Agreement: Partnership Agreement

comprehensive assessment of the KIC, the PA can be extended for another period of a maximum of seven years.

The Grant Agreement (GA)[14] is the contractual instrument laying down the provisions concerning the implementation of the KIC activities (KIC Business Plan, Cross-KIC activities, etc.) through grants, on an annual or multi-annual basis of up to three years with the KICs. Business plans describe the main objectives and expected results and actions taken by the KICs.

In accordance with the Grant Agreement (Annex 5), the KIC launches calls (i.e. open calls or KIC partnership calls) in order to select projects or award prizes. The KIC awards a "financial support to third parties" (i.e. the so called "subgrants" and "prizes") for the implementation of these projects and signs subgrant agreements ("Financial Support Agreements") with the selected entities or consortia.

[14] Horizon Europe Model Grant Agreement: general-mga_horizon-euratom_en.pdf

11 About EIT Health

11.1 Vision and mission

EIT Health was established in 2015, as a 'knowledge and innovation community' (KIC) of the European Institute of Innovation and Technology (EIT) as strong, diverse and balanced European Partnership of best-in-class organisations in education, research, technology, business creation and corporate and social innovation. EIT Health is supported by the EIT, a body of the EU.

EIT Health's vision is 'To enable people in Europe to live longer, healthier lives by building and growing businesses to create products and services that progress healthcare in Europe, while strengthening our economy and the sustainability of our healthcare systems.'

EIT Health's mission is: 'By 2030, we'll be Europe's leading innovation platform, facilitating longer, healthier lives and more sustainable healthcare systems.'

11.2 Strategic Objectives

Strengthening healthcare systems in Europe

The cross-KIC pathway can help relevant ventures access market, technology and ecosystem knowledge needed to address barriers to innovation and international growth.

Promoting better health of citizens

Where health-relevant ventures participate, RIB Poland supports the development and routing of solutions with potential value for citizens, patients and healthcare systems.

Contributing to a sustainable health economy in Europe

The programme strengthens the commercial readiness of high-potential ventures and helps connect them to appropriate EIT Community growth and investment pathways.

12 Overview of Participating KICs

12.1 EIT Community Regional Innovation & Internationalisation Cluster and EIT Regional Innovation Booster Poland

The EIT Community Regional Innovation and Internationalisation Cluster (RI&I) provides the cross-KIC framework for collaboration on EIT Regional Innovation Booster (RIB). In RIB Poland, EIT Health coordinates the Call and programme delivery. Relevant KIC representatives may contribute thematic, technology, market, and investment knowledge as appropriate.

12.1.1 Memorandum of Cooperation participation

A KIC may participate through a Memorandum of Cooperation rather than as a core member of the RI&I Cluster. Participation through a memorandum of cooperation follows the relevant KIC's agreed role, resources and own decision-making procedures.

12.2 Overview of EIT Health

EIT Health is a European health innovation network connecting companies, universities, research centres, hospitals and other stakeholders. It supports the development, validation, commercialisation and scaling of health innovations through entrepreneurship, Business Creation, market access, investment and ecosystem activities. EIT Health acts as Programme Lead for this Call.

12.3 Overview of EIT Digital / 28DIGITAL

EIT Digital / 28DIGITAL mobilises a European ecosystem of corporations, SMEs, start-ups, universities, research institutes, entrepreneurs and investors working on digital transformation. Its capabilities support the growth of digital ventures through technology, talent, business-development and market-access activities.

12.4 Overview of EIT Food

EIT Food supports innovation across the agrifood value chain, including sustainable food systems, nutrition, resource efficiency, traceability and food-tech entrepreneurship. It connects business, research, entrepreneurs and consumers to bring agrifood technologies and products to market.

12.5 Overview of EIT InnoEnergy

EIT InnoEnergy operates in the sustainable-energy transition, supporting innovation in energy storage, renewables, electrification, energy efficiency, smart grids, sustainable buildings and energy-intensive industries. It connects technology, entrepreneurship, investment and industrial partners.

12.6 Overview of EIT Raw Materials

EIT Raw Materials supports innovation across the raw-materials value chain, including critical materials, recycling, substitution, circularity, processing and industrial side streams. Its ecosystem helps ventures address Europe's raw-materials supply, sustainability and competitiveness challenges.

12.7 Overview of EIT Urban Mobility

EIT Urban Mobility supports more sustainable, integrated and liveable urban mobility systems. It connects cities, businesses, start-ups, universities, research organisations and other stakeholders with market, talent, funding and knowledge opportunities.

12.8 Overview of EIT Culture & Creativity

EIT Culture & Creativity supports innovation, education, business creation and societal impact across Europe's cultural and creative sectors. Its areas include architecture, gaming, fashion, cultural heritage, audiovisual media and creative technologies.

12.9 Overview of Climate KIC

Climate KIC supports the development and scaling of innovations for climate change mitigation, adaptation and resilience. Its work includes decarbonisation, climate-neutral cities, circular economy and sustainable systems transformation. It connects entrepreneurs, businesses, cities, researchers and investors with climate-impact expertise, business support, networks and opportunities to develop and scale climate solutions.